Arrakis Therapeutics Presents Data on RNA-Targeted Small Molecule Drug Program for Myotonic Dystrophy at Cell Symposia Conference

Dec 04, 2024•about 1 year ago

WalthamTherapeuticsHealth CareBiotechnology

Product Description

Arrakis Therapeutics has announced the presentation of data for its RNA-targeted small molecule drug program aimed at treating myotonic dystrophy type 1 (DM1). The preclinical results highlight the company's innovative approach to drug design targeting RNA.

Company Information

Company

Arrakis Therapeutics, Inc.

Location

830 Winter Street

Waltham, Massachusetts, United States

About

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. Arrakis brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors.

Product Launch Insights

Based on market data

Market expansion signals

New product launches often coincide with market expansion initiatives

Arrakis Therapeutics Presents Data on RNA-Targeted Small Molecule Drug Program for Myotonic Dystrophy at Cell Symposia Conference

Product Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Product Launch Insights

Related People

Company Information